MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma
Advanced Science · 2025-12 · 12 (47)
DOI: 10.1002/advs.202514600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.10.2025. Verfasst von Jiayuan Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Tumor-Associated Macrophages, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Natural Science Foundation of China, Education Ministry's Chunhui Program Cooperative Research Project.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapy, especially in combination regimens, has significantly increased survival of renal cell carcinoma (RCC) patients. However, the ICB‐resistant mechanisms remain largely unclear and require further investigation. Here, an immunosuppressive ecosystem in ICB‐resistant tumors is identified, featured by preferential infiltration of MARCO+ tumor‐associated macrophages (TAMs) and restrained cytotoxicity of CD8+ cytotoxic T lymphocytes (CTLs). The infiltrated MARCO+ TAMs can obstruct the development of CD8+ CTLs by impairing MHC‐I‐mediated neoantigen cross‐presentation. Mechanistically, MARCO up‐regulates the expression of SOCS1, which obstructs the kinase activity of JAK1, thereby downregulating MHC‐I expression through the inhibition of the JAK1‐STAT1‐NLRC5 signaling cascade. Further, MARCO blockade significantly facilitates ICB therapy in in vivo models by recovering tumor recognition and priming anti‐tumor CD8+ T cell responses. Taken together, these findings highlight MARCO as a highly desirable target in ICB‐refractory individuals for immunorecognition reignition and immunotherapy modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Peking University, Beijing, 100142, China.
- Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Peking University, Beijing, 100142, China.
ORCID-Profile: Xinan Sheng
Förderung
- Beijing Natural Science Foundation
- Natural Science Foundation of China
- Education Ministry's Chunhui Program Cooperative Research Project
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Mo, J., Wei, J., Qu, M., Dai, J., Kong, Y., Xu, H., Li, J., Yan, X., Cui, C., Si, L., Chi, Z., Guo, J., Wu, X., & Sheng, X. (2025). MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma. Advanced Science, 12(47). https://doi.org/10.1002/advs.202514600
Vancouver
Chen J, Mo J, Wei J, Qu M, Dai J, Kong Y, et al. MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma. Advanced Science. 2025;12(47). doi:10.1002/advs.202514600
BibTeX
@article{Chen2025,
author = {Chen, Jiayuan and Mo, Jiazhi and Wei, Jinchang and Qu, Mengnan and Dai, Jie and Kong, Yan and Xu, Huayan and Li, Juan and Yan, Xieqiao and Cui, Chuanliang and Si, Lu and Chi, Zhihong and Guo, Jun and Wu, Xiaowen and Sheng, Xinan},
title = {MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {47},
doi = {10.1002/advs.202514600}
}
EUVIMED